Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide in T2DM Patients Failing Other GLP-1 Analog
NCT02767596Phase 4Terminated
- Sponsor
- Laniado Medical Center
- Start
- Jul 2016
- Primary completion
- Feb 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Laniado Medical Center. Primary endpoints: Change in hemoglobin A1c at 16 weeks and Change in body weight at 16 weeks. Started Jul 2016; status: terminated.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02767596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767596.